Evidence map›Paper›PMID 24147517›Full record

ArticleExpert review of cardiovascular therapy2013

Implementation of cardovascular cell therapy network trials: challenges, innovation and lessons learned from experience in the CCTRN.

Ki E Park, Lemuel A Moyé, Timothy D Henry, Emerson C Perin, Shelly L Sayre, Judy Bettencourt, Rachel W Vojvodic, Rachel E Olson, Carl J Pepine, CCTRN

Abstract read
In one paragraph

Article in Expert review of cardiovascular therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ki E ParkUniversity of Florida College of Medicine, 1600 SW Archer Rd. Gainesville, FL 32610, USA.
Lemuel A Moyé
Timothy D Henry
Emerson C Perin
Shelly L Sayre
Judy Bettencourt
Rachel W Vojvodic
Rachel E Olson
Carl J Pepine
CCTRN

Funding

Data Coordinating Center For The Cardiovascular Cell Therapy Research NetworkUM1HL087318 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DAVIS, BARRY R · 2012 to 2018
$29.8M
MN Regional Cardiovascular Cell Therapy Clinical Res. Network: From AMI to PADUM1HL087394 · NHLBI · UNIVERSITY OF MINNESOTA · PI HENRY, TIMOTHY D · 2012 to 2018
$5.1M
UFRCC for Cardiovascular Cell Therapy Research NetworkUM1HL087366 · NHLBI · UNIVERSITY OF FLORIDA · PI PEPINE, CARL J · 2012 to 2018
$4.7M
NHLBI NIH HHS 5 UM1 HL087318-07.NHLBI NIH HHS UM1 HL087318NHLBI NIH HHS UM1 HL087366NHLBI NIH HHS UM1 HL087394
6 · The paper itself

Abstract

The cardiovascular cell therapy network was developed by the National Heart, Lung and Blood Institute to design and conduct clinical trials to advance the field of cardiovascular (CV) cell-based therapy. The Cardiovascular Cell Therapy Network successfully completed three clinical trials involving approximately 300 subjects across five centers and six satellites. Although the concept of a network within clinical trials research is not new, the knowledge gained in the implementation of such large-scale trials, particularly in novel therapeutic areas such as cell therapy is not often detailed in the literature. The purpose of this communication is to summarize key factors in achieving network goals and share the knowledge gained to promote success in future cardiovascular disease cell therapy trials and networks.

Indexed as

Cardiovascular DiseasesCell- and Tissue-Based TherapyClinical Trials as TopicHumansNational Heart, Lung, and Blood Institute (U.S.)United States

Identifiers

PMID24147517
PMCPMC4117343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.